Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density

Climacteric

Volumn 10, Issue 3, 2007, Pages 249-256

  Lundstrom E ^a,b   Bygdeson, M ^a   Svane, G ^a   Azavedo, E ^a   Von Schoultz, B ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Estradiol norethisterone acetate; Hormone replacement therapy; Mammographic breast density; Ultra low dose

Indexed keywords

ESTRADIOL; NORETHISTERONE ACETATE; PLACEBO;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY DENSITY; BREAST; BREAST DENSITY; BREAST DISCOMFORT; BREAST DISEASE; BREAST EXAMINATION; BREAST TENDERNESS; CLINICAL TRIAL; COMPUTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MAMMOGRAPHY; MASTALGIA; MULTICENTER STUDY; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT;

ADULT; AGED; BREAST; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE; SWEDEN; TREATMENT OUTCOME;

EID: 34248588090     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701385805     Document Type: Article

References (33)

1. Barrett-Connor E, Grady D, Stefanick ML. The rise and fall of menopausal hormone therapy. Annu Rev Public Health 2005;26:115-40
2. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
3. Chlebowski RT, Hendrix SL, Langer RD, et al. WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53
4. Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27
5. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-57
6. Druckmann R. Progestins and their effects on the breast. Maturitas 2003;46:56-69
7. Miller WR, Langdon SP. Steroid hormones and cancer. III. Lessons from experimental systems. Eur J Surg Oncol 1997;23:163-77
8. Boyd NF, Rommens JM, Vogt K, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 2005;6:798-808
9. Warren R. Hormones and mammographic breast density. Maturitas 2004;49:67-78
10. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356:227-36
11. Lundström E, Wilczek B, von Palffy Z, et al. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 1999;181:348-52
12. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/ Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130:262-9
13. Lundström E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186:717-22
14. Conner P, Svane G, Azavedo E, et al. Mammographic breast density, hormones and growth factors during continuous combined hormone therapy. Fertil Steril 2004;81:1617-23
15. Panay N, Ylikorkala O, Archer DF, et al. Ultra-low-dose estradiol and norethisterone acetate: effective menopause symptom relief. Climacteric 2007;10:120-31
16. Lundström E, Wilczek B, von Palffy Z, et al. Mammographic breast density during HRT: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens. Climacteric 2001;4:42-8
17. Wolfe JN. Breast patterns as an index of risk for developing breast cancer. Am J Roentgenol 1976;26:1130-9
18. Byng JW, Boyd NF, Jong RA, et al. Quantitative analysis of mammographic parenchymal densities. Phys Med Biol 1994;39:1629-38
19. Byng JW, Boyd NF, Fishell E, et al. Automated analysis of mammographic densities. Phys Med Biol 1996;41:909-23
20. Lundström E, Söderqvist G, Svane G, et al. Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate; a pilot study. Fertil Steril 2006;85:989-95
21. Vachon CM, Brandt KR, Ghosh K, et al. Mammographic breast density as a general marker of breast cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16:43-9
22. Boyd NF, Lockwood GA, Martin LJ, et al. Mammographic density as a marker of susceptibility to breast cancer: a hypothesis. IARC Sci Publ 2001;154:163-9
23. Boyd NF, Stone J, Martin LJ, et al. The association of breast mitogens with mammographic densities. Br J Cancer 2002;87:876-82
24. Conner P. Breast response to menopausal hormone therapy - aspects on proliferation, apoptosis and mammographic density. Ann Med 2007;39:28-41
25. Conner P, Söderqvist G, Skoog L, et al. Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology. Breast Cancer Res Treat 2003;78:159-65
26. Hofling M, Lundström E, Azavedo E, et al. Testosterone addition during menopausal hormone therapy: effects on mammographic breast density. Climacteric 2007;10:155-63
27. Lundström E, Sahlin L, Skoog L, et al. Expression of Syndecan-1 in histologically normal breast tissue from postmenopausal women with breast cancer according to mammographic density. Climacteric 2006;9:277-82
28. Alowami S, Troup S, Al-Haddad S, et al. Mammographic density is related to stroma and stromal proteogycan expression. Breast Cancer Res 2003;5:129-35
29. Imagawa W, Pedchenko VK, Helber J, et al. Hormone/growth factors interactions mediating epitelial/stromal communication in mammary gland development and carcinogenesis. J Steroid Biochem Mol Biol 2002;80:213-30
30. The North American Menopause Society. Position Statement on Estrogen and Progestogen use in peri- and postmenopausal women. Menopause 2007;14:168-82
31. EMEA Public Statement on Recent Publications Regarding Hormone Replacement Therapy. Available at: http://www.emea.eu.int/pdfs/human/press/pus/ 3306503en.pdf (accessed October 13, 2005)
32. Peeyananjarassri K, Baber R. Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. Climacteric 2005;8:13-23
33. Grady D, Vittinghoff E, Lin F, et al. Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women. Menopause 2007, Jan 11, Epub ahead of print